Word Learning in Deaf Children Using Eye-tracking and Behavioral Measures
Launched by BOSTON UNIVERSITY CHARLES RIVER CAMPUS · Aug 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how deaf children learn words, specifically looking at a concept called "mutual exclusivity." This means that children might think that each word only refers to one specific thing. For example, if they learn the sign for "dog," they might not think that the same word can refer to something else, like a "cat." The researchers want to see if this idea applies to deaf children who use American Sign Language (ASL) and whether it works differently for those who learn both ASL and spoken language.
To participate in this study, children need to be between 18 to 60 months old and have been born severely to profoundly deaf. They can have either deaf or hearing parents, but they must communicate using ASL and have normal or corrected vision. Unfortunately, children who have not been exposed to ASL cannot take part. If eligible, participants will engage in fun activities that help researchers understand how they learn words in their everyday lives. This study could provide valuable insights into language development in deaf children, which can help improve teaching methods and resources for them in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Deaf children ages 18-60 months
- • born severely to profoundly deaf
- • have either deaf or hearing parents
- • communicate using American Sign Language
- • have normal to corrected normal vision
- Exclusion Criteria:
- • Deaf children who have not been exposed to American Sign Language
About Boston University Charles River Campus
Boston University Charles River Campus is a prominent academic institution dedicated to advancing health and science through innovative research and education. As a sponsor of clinical trials, the campus leverages its extensive resources and interdisciplinary expertise to facilitate groundbreaking studies that aim to improve patient outcomes and contribute to the understanding of various medical conditions. With a commitment to ethical research practices and collaboration with healthcare professionals, Boston University Charles River Campus plays a vital role in translating scientific discoveries into clinical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Amy Lieberman, PhD
Principal Investigator
Boston University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported